Ip M M, Milholland R J, Rosen F, Kim U
Cancer Res. 1981 Mar;41(3):984-8.
The effect of the antiestrogen tamoxifen on growth of the transplantable autonomous mammary tumor MTW-9B was compared with its effects on progesterone and estrogen receptor levels. Growth of the tumor was similar in intact rats, ovariectomized rats, or ovariectomized rats given estradiol, in both the presence and the absence of tamoxifen. Progesterone receptor levels, however, were reduced by ovariectomy and restored by estrogen administration. Tamoxifen antagonized this effect of estrogen, although when administered by itself to ovariectomized rats it acted as an agonist, since progesterone receptor levels were induced. Cytosol estrogen receptor was depleted by tamoxifen in both intact and ovariectomized rats. In uterus from the same animals, tamoxifen also showed both antagonist and agonist properties, although here too there was an apparent dissociation between effects on growth and progesterone receptor levels. We conclude from these experiments that: (a) the estrogen receptor complex may be acting at more than one site on the genome; and (b) regulation of progesterone receptor levels by estrogen (or tamoxifen) does not necessarily predict sensitivity of tumor growth to antiestrogens.
将抗雌激素药物他莫昔芬对可移植性自主乳腺肿瘤MTW - 9B生长的影响与其对孕激素受体和雌激素受体水平的影响进行了比较。在有或没有他莫昔芬的情况下,完整大鼠、去卵巢大鼠或给予雌二醇的去卵巢大鼠的肿瘤生长情况相似。然而,孕激素受体水平在去卵巢后降低,而雌激素给药可使其恢复。他莫昔芬拮抗雌激素的这种作用,尽管单独给予去卵巢大鼠时它表现为激动剂,因为可诱导孕激素受体水平。在完整大鼠和去卵巢大鼠中,他莫昔芬均使胞质雌激素受体减少。在同一动物的子宫中,他莫昔芬也表现出拮抗和激动特性,尽管此处对生长和孕激素受体水平的影响之间也存在明显的分离。我们从这些实验中得出结论:(a)雌激素受体复合物可能在基因组的多个位点起作用;(b)雌激素(或他莫昔芬)对孕激素受体水平的调节不一定预示肿瘤生长对抗雌激素的敏感性。